Insight Surgery opens new Centre of Excellence at Manchester Science Park, UK
Insight Surgery increases their manufacturing capabilities and prescence in the UK with the opening of a new state…
Precision Engineered Patient-Specific Medical Devices to Enhance Surgical Outcomes
FDA-cleared and ISO 13485 certified, Insight Surgery delivers regulated, high-quality medical devices throughout the United States and United Kingdom. Our mission is straightforward: to enable safer, more efficient surgery through precision-engineered devices that align with each patient’s unique anatomy and each surgeon’s clinical objective of delivering optimal outcomes.
Insight Surgery are the archetype of innovative MedTech businesses that Nodenza has invested in. They are delivering value to patients and surgeons today, not tomorrow. With the benefit of our support the team is poised to become a global market leader including US personalized surgery market.”
Our Team
Our Board and Management team consists of highly seaseoned industry leaders in Venture Capital, creation and Exiting of med-techs, Business, Finance, Legal, Technology and Medical. We have a world class team of biomedical engineers, clinical specialists, regulatory experts and digital manufacturing professionals working side by side with surgeons to pioneer the future of personalised surgery.
Carsten Thiel
Chairman | Insight SurgeryAdvisory Board Member | Nodenza Venture Partners
Carsten is a visionary leader with a strong science-based background with PhD in Molecular Biology from Max-Planck Institute. Carsten’s career has been commercially focused in both public and private companies with the highlight of generating >4x IRR with the successful exit of EUSA Pharma.
His core expertise lies in turning businesses around, driving significant top and bottom-line growth, managing small and large teams, M&A activities and integration, building, restructuring and revitalizing capability. Carsten has been recognized as one of “The Top 25 Healthcare Technology CEOs of Europe.
Henry Pinchbeck
Chief Executive Officer | Director | Insight SurgeryHenry read Bio-sciences at Edinburgh University before converting to law. He worked as a commercial and real-estate solicitor in the City of London for 10 years and then moved “in-house” at first for larger companies, and then for a series of SMEs.
As a Founder and CEO of Insight Surgery he leads the team on US and UK strategic matters, as well as any legal or regulatory issues.
Paul Fotheringham
Founder | Chief Technology Officer | Director | Insight SurgeryPaul is the original Founder of Insight Surgery and has an academic background as a Computer / AI and Management Scientist from the University of Edinburgh. He is a seasoned Technologist, Entrepreneur and Med-tech expert.
Over his 15 year corporate career as a Technical Programme Manager, Enterprise Architect and CTO he has worked for large corporates including Enron, the London Stock Exchange, British Petroleum and Macquarie Investment Group in over 10 global locations including NYC, London, Seoul, Hong Kong, Tokyo and Nairobi.
He is a globally respected Leader with his entrepreneurial expertise in developing sustainable Medical SME’S and Additive Manufacturing.
Ross Morton
Non-Executive Director | Insight SurgeryManaging Partner | Nodenza Venture PartnersRoss founded Nodenza and leads the Fund in identifying new investment opportunities, engaging with Limited Partners and day to day operations. He sits on the Investment Committee.
Ross was COO of Akaza Bioscience, sold to Aquarious Bio in 2022. Prior, he was on the management team of Izana Bioscience, which sold to one of the Roivant companies in 2020.
Previously, Ross was a management consultant in the Advisory practice at Kinapse, a Syneos company supporting Big Pharma R&D projects.
Dr Dev Kumar
Non-Executive Director | Insight SurgeryPartner | Nodenza Venture PartnersDev leads the Legal & Intellectual Property needs of portfolio companies. An expert in guiding the transaction and commercial aspects of investments, Dev sits on the Investment Committee.
Dev is dually qualified as a lawyer & medical doctor. He focuses on corporate, regulatory, and IP matters with a specialist interest in pricing & reimbursement.
Most recently General Counsel of EUSA Pharma, Dev now sits on various Boards.He previously held positions at Biogen, UCB, Boehringer Ingelheim, & the University of Oxford.
David Lembo
Chief Commercial Officer | Insight SurgeryDavid Lembo is a senior commercial leader with over 20 years of experience in orthopedic medical technology. He previously held leadership roles at Arthrex, OrthoPediatrics, and CarboFix Orthopedics, driving innovative product launches, building high-performing teams, and expanding U.S. and international markets. David holds a Masters in Finance from the University of Notre Dame and an MBA from Thunderbird School of Global Management.
Press Room
Explore Insight Surgery's latest press releases
Insight Surgery's new Centre of Excellence at Manchester Science Park, UK, showcases modern healthcare facilities and innovative medical services. 
The image shows the modern exterior of Insight Surgery, a leading healthcare facility with advanced medical services. Children’s Nebraska Partners with Insight Surgery to Advance Pediatric Care Through Personalized Surgical Devices and Services
Read about Insight Surgery’s partnership with Children’s Nebraska to advance pediatric care through personalized surgical devices and virtual…
Insight Surgery logo, highlighting the company's focus on personalized surgical care and US expansion. Insight Surgery completes $2.5m Series A led by Nodenza Venture Partners for US expansion of personalized surgery
Discover Insight Surgery’s $2.5m Series A funding led by Nodenza Venture Partners to expand personalised surgical solutions and…
Join our team!
Click on the links below to learn more about current opportunities at Insight Surgery and apply.
The presence of the guide allows more accurate localisation of the tumor meaning that the operative exposure is less; the risk of damaging nearby structures is less (which also has the knock on effect of reducing post surgical complications and therefore litigation) and the tumour resection is more precise. As the exposure is less patients, they should recover quicker and therefore should go home quicker. Surgical time is reduced meaning that an additional case can potentially be added to the list. The return to theater rate for a positive margin should be less.”